1. Home
  2. IPHA vs ANTX Comparison

IPHA vs ANTX Comparison

Compare IPHA & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$2.05

Market Cap

165.3M

Sector

Health Care

ML Signal

N/A

Logo AN2 Therapeutics Inc.

ANTX

AN2 Therapeutics Inc.

N/A

Current Price

$5.98

Market Cap

172.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IPHA
ANTX
Founded
1999
2017
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.3M
172.9M
IPO Year
2014
2022

Fundamental Metrics

Financial Performance
Metric
IPHA
ANTX
Price
$2.05
$5.98
Analyst Decision
Strong Buy
Buy
Analyst Count
4
1
Target Price
$5.75
$2.00
AVG Volume (30 Days)
184.0K
201.3K
Earning Date
03-26-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.56
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$180.36
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.18
$1.00
52 Week High
$2.71
$7.19

Technical Indicators

Market Signals
Indicator
IPHA
ANTX
Relative Strength Index (RSI) 46.64 59.20
Support Level $1.67 $3.91
Resistance Level $2.29 $7.05
Average True Range (ATR) 0.08 0.32
MACD -0.03 -0.01
Stochastic Oscillator 6.67 75.63

Price Performance

Historical Comparison
IPHA
ANTX

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

Share on Social Networks: